Prospective teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and loss of CYP26 activity

Current Pharmaceutical Design

Volumn 13, Issue 29, 2007, Pages 3020-3037

  McCaffery, P J ^a   Simons, C ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Catabolism; Caudal regression; CYP26; Hippocampus; Limb defect; Neurogenesis; Retinoic acid

Indexed keywords

CISPLATIN; CYPROTERONE ACETATE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; CYTOCHROME P450 REDUCTASE; INTERFERON; LIAROZOLE FUMARATE; N [4 [2 ETHYL 1 (1H 1,2,4 TRIAZOL 1 YL)BUTYL]PHENYL] 2 BENZOTHIAZOLAMINE; PROMETHAZINE; R 115688; R 116010; RETINOIC ACID DERIVATIVE; TETRALIN DERIVATIVE; UNCLASSIFIED DRUG; WNT3 PROTEIN;

CLINICAL TRIAL; DRUG BINDING SITE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; EMBRYOTOXICITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME REGULATION; ENZYME SYNTHESIS; GENE EXPRESSION; GENE MUTATION; HIPPOCAMPUS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROTOXICITY; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEIN FAMILY; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TERATOGENICITY; TERATOLOGY; TRANSCRIPTION INITIATION; UNSPECIFIED SIDE EFFECT;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; TERATOLOGY; TETRALONES; TRETINOIN;

EID: 36248991383     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207782110534     Document Type: Review

References (156)

1. McCaffery P, Drager UC. Regulation of retinoic acid signaling in the embryonic nervous system: A master differentiation factor. Cytokine Growth Factor Rev 2000; 11: 233-49.
2. Ross SA, MeCaffery PJ, Drager UC, De Luca LM. Retinoids in embryonal development. Physiol Rev 2000; 80: 1021-54.
3. Clagett-Dame M, DeLuca HF. The role of vitamin A in mammalian reproduction and embryonic development. Annu Rev Nutr 2002; 22: 347-81.
4. Maden M. Retinoid signalling in the development of the central nervous system. Nat Rev Neurosci 2002; 3: 843-53.
5. Ray W, Bain G, Yao M, Gottlieb DI. CYP29, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. J Biol Chem 1997; 272: 18702-8.
6. Hollemann T, Chen Y, Grunz H, Pieler T. Regionalized metabolic activity establishes boundaries of retinoic acid signalling. EMBO J 1998; 17: 7361-72.
7. McCaffery P, Wagner E, O'Neil J, Petkovich M, Drager UC. Dorsal and ventral retinoic territories defined by retinoic acid synthesis, break-down and nuclear receptor expression. Mech Dev 1999; 85: 203-14
8. Abu-Abed S, Dolle P, Metzger D, Beckett B, Chambon P, Petkovich M. The retinoic acid-metabolizing enzyme, CYP26A1, is essential for normal hindbrain patterning, vertebral identity, and development of posterior structures. Genes Dey 2001; 15: 226-40.
9. MacLean G, Abu-Abed S, Dolle P, Tahayato A, Chambon P, Petkovich M. Cloning of a novel retinoic-acid metabolizing cytochrome P450, Cyp26B1, and comparative expression analysis with Cyp26A1 during early murine development. Mech Dev 2001; 107: 195-201.
10. Sakai Y, Meno C, Fujii H, Nishino J, Shiratori H, Saijoh Y, et al. The retinoic acid-inactivating enzyme CYP26 is essential for establishing an uneven distribution of retinoic acid along the anterio-posterior axis within the mouse embryo. Genes Dev 2001; 15: 213-25.
11. Abu-Abed S, MacLean G, Fraulob V, Chambon P, Petkovich M, Dolle P. Differential expression of the retinoic acid-metabolizing enzymes CYP26A1 and CYP26B1 during murine organogenesis. Mech Dev 2002; 110: 173-7.
12. Yashiro K, Zhao X, Uehara M, Yamashita K, Nishijima M, Nishino J, et al. Replation of retinoic acid distribution is required for proximodistal patterning and outgrowth of the developing mouse limb. Dev Cell 2004; 6: 411-422.
13. McCaffery PJ, Adams J, Maden M, Rosa-Molinar E. Too much of a good thing: Retinoic acid as an endogenous regulator of neural differentiation and exogenous teratogen. Eur J Neurosci 2003; 18: 457-72.
14. Denis L, Debruyne F, De Porre P, Bruynseels J. Early clinical experience with liarozole (Liazal) in patients with progressive prostate cancer. Eur J Cancer 1998; 34: 469-75.
15. Miller WHJ. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer 1998; 83: 1471-82
16. Goss PE, Strasser K, Marques R, Clemons M, Oza A, Goel R, et al. Liarozole fumarate (R85246): In the treatment of ER negative, tamoxifen refractory or chemotherapy resistant postmenopausal metastatic breast cancer. Breast Cancer Res Treat 2000; 64: 177-88.
17. Patel JB, Huynh Ck, Handratta VD, Gediya LK, Brodie AM, Goloubeva OG, et al. Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice. J Med Chem 2004; 47: 6716-29.
18. Huynh CK, Brodie AM, Njar VC. Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. Br J Cancer 2006; 94: 513-23.
19. Njar VC, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 2006; 14: 4323-40.
20. Kumar R, Thompson EB. The structure of the nuclear hormone receptors. Steroids 1999; 64: 310-9.
21. Mark M, Ghyselinck NB, Chambon P. Function of retinoid nuclear receptors: Lessons from genetic and pharmacological dissections of the retinoic acid signalling pathway during mouse embryogenesis. Annu Rev Pharmacol Toxicol 2006; 46: 451-80.
22. Yee SW, Jarno L, Gomaa MS, Elford C, Ooi L-L, Coogan MP, et al. Novel tetralone-derived retinoic acid metabolism blocking agents: synthesis and in vitro evaluation with liver microsomal and MCF-7 CYP26A1 cell assays. J Med Chem 2005; 48: 7123-31.
23. Levin AA, Sturzenbecker LJ, Kazmer S, Bosakowski T, Huselton C, Allenby G, et al. 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRalpha. Nature 1992; 355: 359-61.
24. Mangelsdorf DJ, Borgmeyer U, Heyman RA, Zhou JY, Ong ES, Oro AE, et al. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 1992; 6: 329-44.
25. Kliewer SA, Umesono K, Evans RM, Mangelsdorf DJ. The retinoid X receptors. Modulators of multiple hormonal signaling pathways. In: Blumhoff R, editor. Vitamin A in health and disease. New York, Basel, Hong Kong: Marcel Dekker, Inc.; 1994; 239-55.
26. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: From genes to physiology. Recent Prog Horm Res 2001; 56: 239-63.
27. Solomin L, Johansson CB, Zetterstrom RH, Bissonnette RP, Heyman RA, Olson L, et al. Retinoid-X receptor signalling in the developing spinal cord. Nature 1998; 395: 398-402.
28. Sporn MB, Roberts AB, Goodman DS. The Retinoids: Biology, Chemistry, and Medicine. 2nd edition ed. New York: Raven Press; 1994.
29. Duester G. Families of retinoid dehydrogenases regulating vitamin A function: Production of visual pigment and retinoic acid. Eur J Biochem 2000; 267: 4315-24.
30. Drager UG, Wagner E, McCaffery P. Aldehyde dehydrogenases in the generation of retinoic acid in the developing vertebrate: A central role of the eye. J Nutr 1998; 128: 463S-6S.
31. Gavalas A. ArRAnging the hindbrain. Trends Neurosci 2002; 25: 61-4.
32. White JA, Guo YD, Baetz K, Beckett-Jones B, Bonasoro J, Hsu KE, et al. Identification of the retinoic acid inducible all-trans-retinoic acid 4-hydroxylase. J Biol Chem 1996; 271: 29922-7.
33. Tahayato A, Dolle P, Petkovich M. Cyp26C1 enoodes a novel retinoic acid-metabolizing enzyme expressed in the hindbrain, inner ear, first branchial arch and tooth buds during murine development. Gene Expr Patterns 2003; 3: 449-54.
34. Swindell EC, Thaller C, Sockanathan S, Petkovich M, Jessell TM, Eichele G. Complementary domains of retinoic acid production and degradation in the early chick embryo. Dev Biol 1999; 216: 82-96.
35. Fujii H, Sato T, Kaneko S, Gotoh O, Fujii-Kuriyama Y, Osawa K, et al. Metabolic inactivation of retinoic acid by a novel P450 differentially expressed in developing mouse embryos. EMBO J 1997; 16: 4163-73.
36. Chithalen JV, Luu L, Petkovich M, Jones G. HPLC-MS/MS analysis of the products generated from all-trans-retinoic acid using recombinant human CYP26A. J Lipid Res 2002; 43: 1133-42.
37. Idres N, Marill J, Flexor MA, Chabot GG. Activation of retinoic acid receptor-dependent transcription by all-trans-retinoic acid metabolites and isomers. J Biol Chem 2002; 277: 31491-8.
38. Pijnappel WW, Hendriks HF, Folkers GE, van den Brink CE, Dekker EJ, Edelenbosch C, et al. The retinoid ligand 4-oxo-retinoic acid is a highly active modulator of positional specification. Nature 1993; 366: 340-4.
39. Blumberg B, Bolado J, Jr., Derguini F, Craig AG, Moreno TA, Chakravarti D, et al. Novel retinoic acid receptor ligands in Xenopus embryos. Proc Natl Acad Sci USA 1996; 93: 4873-8.
40. Reijntjes S, Blentic A, Gale E, Maden M. The control of morphogen signalling: Regulation of the synthesis and catabolism of retinoic acid in the developing embryo. Dev Biol 2005; 285: 224-37.
41. Abu-Abed S, Dolle P, Metzger D, Wood C, Maclean G, Chambon P, et al. Developing with lethal RA levels: Genetic ablation of Rarg can restore the viability of mice lacking Cyp26a1. Development 2003; 130: 1449-59.
42. Weston AD, Blumberg B, Underhill TM. Active repression by unliganded retinoid receptors in development: Less is sometimes more. J Cell Biol 2003; 161: 223-8.
43. Ahmad N, Mukhtar H. Cytochrome P450: A target for drug dcvelopment for skin diseases. J Invest Dermatol 2004; 123: 417-25.
44. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J. Am. Acad. Dermatol. 2003; 49: 171-82
45. Estey EH, Giles F, Kantarjian H, O'Brien S, Cortes J, Freireich E, et al. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukaemia. Blood 1999; 94: 2230-5.
46. Fenaux P, Chastang C, Chevret S. Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukaemia. Blood 1999; 94: 1192-200.
47. Weiss GR, Liu PY, Alberts DS, Peng YM, Fisher E, Xu MJ, et al. 13-cis-Retinoic acid or all-trans-retinoic acid plus inteferon alpha in recurrent cervical cancer: A Southwest Oncology Group phase II randomized trial. Gynecol Oncol 1998; 71: 386-90.
48. Pettersson F, Colston KW, Dalgleish AG. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 2001; 23: 273-9.
49. Goodman AB, Pardee AB. Evidende for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci USA 2003; 100: 2901-5.
50. Crandall J, Sakai Y, Zhang J, Koul O, Mineur Y, Crusio WE, et al. 13-cis-retinoic acid suppresses hippocampal cell division and hippocampal-dependent learning in mice. Proc Natl Acad Sci USA 2004; 101: 5111-6.
51. Mey J, McCaffery P. Retinoic acid signaling in the nervous system of adult vertebrates. Neuroscientist 2004; 10: 409-21.
52. McCaffery P, Zhang J, Crandall JE. Retinoic acid signaling and function in the adult hippocampus. J Neurobiol 2006; 66: 780-91.
53. Lewis DFV. Guide to cytochromes P450 structure and function. London: Taylor and Francis 2001.
54. Gomaa MS, Yee SW, Milbourne CE, Barbera MC, Simons C, Brancale A. Homology Model of Human Retinoic Acid Metabolising Enzyme Cytochrome P450 26A1 (CYP26A1): Active Site Architecture and Ligand Binding. J Enz Inhib Med Chem 2006; 21: 361-9.
55. Njar VCO, Nnane IP, Brodie AMH. Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids. Bioorg Med Chem Lett 2000; 10: 1905-8.
56. Van Wauwe J, Cpene MC, Goossens J, Cools W, Monbaliu J. Effects of cytochrome P450 inhibitors on the in vivo metabolism of all-trans-retinoic acid in rats. J Pharmacol Exp Ther 1990; 252: 365-9.
57. Kirby AJ, Le Lain R, Maharlouie F, Mason P, Nicholls PJ, Smith HJ, et al. Inhibition of retinoic acid metabolising enzymes by 2-(4- aminophenylmethyl)-6-hydroxy-3,4-dihydronaphthalene-1(2H)-one and related compounds. J Enz Inhib Mod Chem 2003; 18: 27-33.
58. Djikman GA, Van Moorselaar RJA, Van Ginckel R, Van Stratum P, Wouters L, Debruyne FMJ, et al. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adernocarcinomes. J Urol 1994; 151: 217-22.
59. Wouters W, van Dun J, Dillen A, Coene M-C, Cools W, De Coster R. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced metabolism in MCF-7 human breast cancer cells. Cancer Res. 1992; 52: 2841-6.
60. Van Wauwe I, Van Nyen G, Coene MC, Stoppie P, Cools W, Goossens J, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid- mimetic effects in vivo. J Pharmacol Exp Ther 1992; 261: 773-9.
61. Debruyne FMH, Murray R, Fradet Y, Johansson JE, Tyrrell C, Boccardo F, et al. Liarozole - a novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyproterone acetate. Urology 1998; 52: 72-81.
62. Smith HJ, Nicholls PJ, Simons C, LeLain R. Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Exp Opin Ther Patents 2001; 11: 789-824.
63. Stoppie P, Borgers M, Borghgraef P. Dillen L, Goossens J, Sanz G, et al. R115866 inhibits all-trans-retinoic acid metabolism and exerts retinoidal effects in rodent. J Pharmacol Exp Ther 2000; 293: 304-12
64. Aelterman W, Lang Y, Willemsens B, Vervest I, Lents S, De Knaep F. Conversion of the laboratory synthetic route of the N-aryl-2-benzothiazolamine R116010 to a manufacturing method. Org Proc Res Dev 2001; 5: 467-71.
65. Van Heusden J, Van Ginckel R, Bruwiere H, Moelans P, Janssen B, Floren W, et al. Inhibition of all-trans-retinoic acid metabolism by R116010 induces antitumour activity. Br. J. Cancer 2002; 86: 605-11
66. Armstrong JL, Ruiz M, Boddy AV, Redfern CPF, Pearson ADJ, Veal GJ. Increasing the intracellular availability of all-trans retinoic acid in Neuroblastoma cells. Br J Cancer 2005; 92: 696-704.
67. Mulvihill MJ, Kan JLC, Beck P, Bittner M, Cesario C, Cooke A, et al. Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl- amines as retinoic acid metabolism blocking agents (RAMBAs). Bioorg Med Chem Lett 2005; 15: 1669-73.
68. Mulvihill MJ, Kan JLC, Cooke A, Bhagwat S, Beck P, Bittner M, et al. 3-[6-(2-dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2- yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent. Bioorg Med Chem Lett 2006; 16: 2729-33.
69. Njar VCO. Cytochrome P450 retinoic acid 4-hydroxylase inhibitors: potential agents for cancer therapy. Mini Rev Med Chem 2002; 2: 261-9
70. Pautus S, Yee SW, Jayne M, Coogan MP, Simons C. Synthesis and CYP26A1 inhibitory activity of 1-[benzofuran-2-yl-(4-alkyl/ aryl-phenyl)-methyl]-1H-triazoles. Bioorg Med Chem 2006; 14: 3643-53.
71. Vasudevan J, Johnson AT, Huang D, Wang L, Chandraratna RA, inventors; Compounds having activity as inhibitors of cytochrome p450rai. WO 02/ 018361.
72. Pratt WB. The entry, distribution, and elimination of drugs. In: Prat WB, Taylor P, Eds. Principles of Drug Action. 3rd ed. New York: Churchill Livingstone; 1990; 201-96.
73. Goyer RA. Transplacental transport of lead. Environ Health Perspect 1990; 89: 101-5.
74. Dorman DC, Allen -AL, Byezkowski JZ, Claudio L, Fisher JE, Fisher JW, et al. Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: Pharmacokinetic and pharmacodynamic considerations. Environ Health Perspect 2001; 109: 101-11.
75. Faber JJ, Thornburg KL. Permeability of the placental membrane for hydrophilic substances. In: Placental Physiology. New York: Raven Press 1993; 79-89.
76. Maranghi F, Macri C, Ricciardi C, Stazi AV, Mantovani A. Evaluation of the placenta: Suggestion for greater role in developmental toxicology. Adv Exp Med Biol 1998; 444: 129-36.
77. Challier JC, Guerre-Millo M, Nandakumarna M, Gerbaut L, d'Athis P. Clearance of compounds of different molecular size in the human placenta in vitro. Biol Neonate 1985; 48: 143-8.
78. Sibley CP, Bauman KF, Firth JA. Molecular charge as a determinant of macromolecule permeability across the fetal capillary endothelium of the guinea-pig placenta. Cell Tissue Res 1983; 229: 365-77.
79. Thomburg KL, Burry KJ, Adams AK, Kirk EP, Faber JJ. Permeability of placenta to inulin. Am J Obstet Gynecol 1988; 158: 1165-9.
80. Willis DM, O'Grady JP, Faber JJ, Thornburg KL. Diffusion permeability of cynnocobalamin in human placenta. Am J Physiol 1986; 250: R459-64.
81. Hilal SH, Karickhoff SW, Carreirs, LA. A rigorous test for SPARC's chemical reactivity models: Estimation of more than 4300 ionization pKas. Quant Struct Activ Relat 1995; 14(4): 348-55.
82. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13: 477-83.
83. Phie CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-41.
84. Harmon MA, Boehm MF, Heyman RA, Mangelsdorf DJ. Activation of mammalian retinoid X receptors by the insect growth regulator methoprene. Proc Natl Acad Sci USA 1995; 92: 6157-60.
85. Lemotte PK, Keidel S, Apfel CM. Phytanic acid is a retinoid X receptor ligand. Eur J Biochem 1996; 236: 328-33.
86. van den Brink DM, Wanders RJ. Phytanic acid: Production from phytol, its breakdown and role in human disease. Cell Mol Life Sci 2006; 63: 1752-65.
87. Simeone A, Acampora D, Arcioni L, Andrews PW, Boncinelli E, Mavilio F. Sequential activation of Hox2 homeobox genes by retinoic acid in human embryonal carcinoma cells. Nature 1990; 346: 763-6.
88. Chen Y, Huang L, Solursh M. A concentration gradient of retinoids in the early Xenopus laevis embryo. Dev Biol 1994; 161: 70-6.
89. Conlon RA. Retinoic acid and pattern formation in vertebrates. Trends Genet 1995; 11: 314-9.
90. Dupe V, Lumsden A. Hindbrain patterning involves graded responses to retinoic acid signalling. Development 2001; 128: 2199-208.
91. Sirbu IO, Gresh L, Barra J, Duester G. Shifting boundaries of retinoic acid activity control hindbrain segmental gene expression. Development 2005; 132: 2611-22.
92. Reijntjes S, Gale E, Maden M. Generating gradients of retinoic acid in the chick embryo: Cyp26C1 expression and a comparative analysis of the Cyp26 enzymes. Dev Dyn 2004; 230: 509-17.
93. Niederreither K, Subbarayan V, Dolle P, Chambon P. Embryonic retinoic acid synthesis is essential for early mouse post- implantation development. Nat Genet 1999; 21:444-8.
94. Niederreither K, McCaffery P, Drager UC, Chambon P, Dolle P. Restricted expression and retinoic acid-induced downregulation of the retinaldchyde dehydrogenase type 2 (RAIDH-2) gene during mouse development. Mech Dev 1997, 62: 67-78.
95. Padmanahhan R. Retinoic acid-induced caudal regression syndrome in the mouse fetus. Reprod Toxicol 1998; 12: 139-51.
96. Marshall H, Nonchev S, Sham MH, Muchamore I, Lumsden A, Krumlauf R. Retinoic acid alters hindbrain Hox code and induces transformation of rhombomeres 2/3 into a 4/5 identity. Nature 1992; 360: 737-41.
97. Guthrie S. Patterning the hindbrain. Curr Opin Neurobiol 1996; 6: 41-8.
98. Pignatello MA, Kauffman FC, Levin AA. Liarozole markedly increases all trans-retinoic acid toxicity in mouse limb bud cell cultures: A model to explain the potency of the aromatic retinoid (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthylenyl)-1- propenyl) benzoic acid. Toxicol Appl Pharmacol 2002; 178: 186-94.
99. Bowles J, Knight D, Smith C, Wilhelm D, Richman J, Mamiya S, et al. Retinoid signaling determines germ cell fate in mice. Science 2006; 312: 596-600.
100. Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC. Retinoic acid regulates sex-specific timing of meiotic initiation in mice. Proc Natl Acad Sci USA 2006; 103: 2474-9.
101. Taimi M, Helvig C, Wisniewski J, Ramshaw H, White J, Amad M, et al. A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J Biol Chem 2004; 279: 77-85.
102. Sakai Y, Luo T, McCaffery P, Hamada H, Drager UC. CYP26A1 and CYP26C1 cooperate in degrading retinoic acid within the equatorial retina during later eye development. Dev Biol 2004; 276: 143-57.
103. Gu X, Xu F, Wang X, Gao Y, Zhao Q. Molecular cloning and expression of a novel CYP26 gene (cyp26d1) during zebrafish early development. Gene Expr Patterns 2005, 5: 733-9.
104. Otto DME, Henderson CJ, Carrie D, Davey M, Gundersen TE, Blomhoff R, et al. Identification of novel roles of the cytochrome P450 system in early embryogenesis: Effects on vasculogenesis and retinoic acid homeostasis. Mol Cell Biol 2003; 23: 6103-16.
105. Debruyne FJ, Murray R, Fradet Y, Johansson JE, Tyrrelf-C, Boccardo F, et al. Liarozole-a novel treatment approach for advanced prostate cancer: Results of a large randomized trial versus cyproterone acetate. Liarozole Study Group. Urology 1998; 52: 72-81.
106. Jetten AM. Multi-stage program of differentiation in human epidermal keratinocytes: Regulation by retinoids. J Invest Dermatol 1990; 95: 44S-6S.
107. Thomas SS, Prabhu R, Balasubramanian KA. Retinoid metabolism in the rat small intestine. Br J Nutr 2005; 93: 59-63.
108. Maden M, Hind M. Retinoic acid in alveolar development, maintenance and regeneration. Philos Trans R Soc Lond B Biol Sci 2004; 359: 799-808
109. Zouboulis CC. Retinoids-which dermatological indications will benefit in the near future. Skin Pharmacol Appl Skin Physiol 2001; 14:303-15.
110. Niles RM. Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat Res 2004; 555: 81-96.
111. Molteni R, Fumagalli F, Magnaghi V, Roceri M, Gennarelli M, Racagni G, et al. Modulation of fibroblast growth factor-2 by Stress and corticosteroids: From developmental events to adult brain plasticity. Brain Res Brain Res Rev 2001; 37:249-58.
112. Klein R. Eph/ephrin signaling in morphogenesis, neural development and plasticity. Curr Opin Cell Biol 2004; 16: 580-9.
113. Wines-Samuelson M, Shen J. Pres,,,enilins in the developing, adult, and aging cerebral cortex. Neuroscientist 2005; 11: 441-51.
114. Chiang MY, Misner D, Kempermann G, Schikorski T, Giguere V, Sucov HM, et al. An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression. Neuron 1998; 21: 1353-61.
115. Wu G, Fang Y, Lu ZH, Ledeen RW. Induction of axon-like and dendrite-like processes in neuroblastoma, cells. J Neurocytol 1998; 27:1-14.
116. Sapolsky RM. Stress and plasticity in the limbic system. Neurochem Res 2003; 28: 1735-42.
117. Silva AJ. Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. J Neurobiol 2003; 54: 224-37.
118. Krezel W, Kastner P, Chambon P. Differential expression of retinoid receptors in the adult mouse central nervous system. Neuroscience 1999; 89: 1291-300.
119. Zetterstrom RH, Simon A, Giacobini MMJ, Ericksson U, Olson L. Localization of cellular retinoid-binding proteins suggests specific roles for retinoids in the adult central nervous system. Neuroscience 1994; 62: 899-918.
120. Sakai Y, Crandall JE, Brodsky J, McCaffery P. 13-cis Retinoic acid (accutane) suppresses hippocampal cell survival in mice. Ann N Y Acad Sci 2004; 1021: 436-40.
121. Rossant J, Zirngibl R, Cado D, Shago M, Giguère V. Expression of a retinoic acid response element-hsplacZ transgene defines specific domains of transcriptional activity during mouse embryogenesis. Genes Dev 1991; 5: 1333-44.
122. Scharfman HE, Sollas AL, Smith KL, Jackson MB, Goodman JH. Structural and functional Asymmetry in the normal and epileptic rat dentate gyrus. J Comp Neurol 2002; 454: 424-39.
123. Misner DL, Jacobs S, Shimizu Y, de Uriquiza AM, Solomin L, Perlmann T, et al. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci USA 2001; 98: 11714-9.
124. Iniguez MA, Morte B, Rodriguez-Pena A, Munoz A, Gerendasy D, Sutcliffe JG, et al. Characterization of the promoter region and flanking sequences of the neuron-specific gene RC3
125. Wang YZ, Christakos S. Retinoic acid regulates the expression of the calcium binding protein, calbindin-D28K. Mol Endocrinol 1995; 9: 1510-21.
126. Matsuoka I, Mizuno N, Kurihara K. Cholinergic differentiation of clonal rat pheochromocytoma cells (PC12) induced by retinoic acid: Increase of choline acetyltransferase activity and decrease of tyrosine hydroxylase activity. Brain Res 1989; 502: 53-60.
127. Ingraham CA, Maness PF. Tyrosine phosphorylated proteins decrease during differentiation of neuronal and glial cells. Dev Neurosci 1990; 12: 273-85.
128. Andrews PW, Nudelman E, Hakomori SI, Fenderson BA. Different paterns of glycolipid antigens are expressed following differentiation of TERA-2 human embryonal carcinoma cells induced by retinoic acid, hexamethylene bisacetamide (HMBA) or bromodeoxyuridine (BUdR). Differentiation 1990; 43: 131-8.
129. McBurney MW. P19 embryonal carcinoma cells. Int J Dev Biol 1993; 37: 135-40.
130. Bain G, Kitchens D, Yao M, Huettner JE, Gottlieb DI. Embryonic stem cells express neuronal properties in vitro. Dev Biol 1995; 168: 342-57.
131. Hill DP, Robertson KA. Differentiation of LA-N-5 neuroblastoma cells into cholinergic neurons: Methods for differentiation, immunohistochemistry and reporter gene introduction. Brain Res Brain Res Protoc 1998; 2: 183-90.
132. Takahashi J, Palmer TD, Gage FH. Retinoic acid and neurotrophins collaborate to regulate neurogenesis in adult-derived neural stem cell cultures. J Neurobiol 1999; 38: 65-81.
133. Barinaga M. No-new-neurons dogma loses ground. Science 1998; 279: 2041-2.
134. Altman J. Are new neurons formed in the brains of adult mammals? Science 1962; 135: 1127-8.
135. Kaplan MS, Hinds JW. Neurogenesis in the adult rat: Electron microscopic analysis of light radioautographs. Science 1977; 197: 1092-4.
136. Kornack DR, Rakic P. Continuation of neurogenesis in the hippocampus of the adult macaque monkey. Proc Natl Acad Sci USA 1999; 96: 5768-73.
137. Eriksson PS, Perfilieva E, Bjork-Eriksson T, Alborn AM, Nordborg C, Peterson DA, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998; 4: 1313-7.
138. Kempermann G, Kuhn HG, Gage FH. More hippocampal neurons in adult mice living in an enriched environment. Nature 1997; 386: 493-5.
139. Shors TJ, Miesegaes G, Beylin A, Zhao M, Rydel T, Gould E. Neurogenesis in the adult is involved in the formation of trace memories. Nature 2001; 410: 372-6.
140. Vogel G. Neuroscience. New brain cells prompt new theory of depression. Science 2000; 290: 258-9.
141. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-13.
142. Sheline YI. 3D MRI studies of neuroanatomic changes in unipolar major depression: The role of stress and medical comorbidity. Biol Psychiatry 2000; 48: 791-800.
143. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000; 20: 9104-10.
144. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000; 75: 1729-34.
145. Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry 2004; 56: 137-9.
146. Yoshimura S, Takagi Y, Harada J, Teramoto T, Thomas SS, Waeber C, et al. FGF-2 regulation of neurogenesis in adult hippocampus after brain injury. Proc Natl Acad Sci USA 2001; 98: 5874-9.
147. Machold R, Hayashi S, Rutlin M, Muzumdar MD, Nery S, Corbin JG, et al. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron 2003; 39: 937-50.
148. Lee J, Duan W, Mattson MP. Evidence that brain-darived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mide. J Neurochem 2002; 82: 1367-75.
149. Ueki T, Tanaka M, Yamashita K, Mikawa S, Qiu Z, Maragakis NJ, et al. A novel secretory factor, Neurogenesin-1, provides neurogenic environmental cues for neural stem cells in the adult hippocampus. J Neurosci 2003; 23: 11732-40.
150. Wang TW, Zh4ng H, Parent JM. Retinoic acid regulates postnatal neurogenesis in the murine subventricular zone-olfactory bulb pathway. Development 2005; 132: 2721-32.
151. Jacobs S, Lie DC, Decicco KL, Shi Y, Deluca LM, Gage FH, et al. Retinoic acid is required early during adult neurogenesis in the dentate gyrus. Proc Natl Acad Sci USA 2006; 103; 3902-7.
152. Etchamendy N, Enderlin V, Marighetto A, Vouimba RM, Pallet V, Jaffard R, et al. Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced normalization of brain retinoid signaling. J Neurosci 2001; 21: 6423-9.
153. Enderlin V, Alfos S, Pallet V, Garcin H, Azais-Braesco V, Jaffard R, et al. Aging decreases the abundance of retinoic acid (RAR) and triiodothyronine (TR) nuclear receptor mRNA in rat brain: Effect of the administration of retinoids. FEBS Lett 1997; 412: 629-32.
154. Coelho SM, Vaisman M, Carvalho DP. Tumour re-diffierentiation effect of retinoic acid: A novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des 2005; 11 (19): 2525-31.
155. Galve-Roperh I, Aguado T, Rueda D, Velasco G, Guzman M. Endocannabinoids: A new family of lipid mediators involved in the regulation of neural cell development. Curr Pharm Des 2006; 12(18): 2319-25.
156. Webber KM, Casadesus G, Zhu Y, Obrenovich ME, Atwood CS, Perry G, et al. The cell cycle and hormonal fluxes in Alzheimer disease: A novel therapeutic target. Curr Pharm Des 2006; 12(6): 691-7.